Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 2, Coping Behavior, Self Efficacy, Masculinity
Interventions: MANUP; Behavioral
Lead sponsor: North Carolina Central University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable Solid Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Topotecan Hydrochloride, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 11 more

Conditions: Cirrhosis, Adrenal Insufficiency
Interventions: Cosyntropin; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 100 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days, fludarabine 30 mg/m2/d for 3 days, ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells; Biological · Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Neoplasms
Interventions: Fine-Needle Biopsy (FNB); Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 100 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Type 2 Diabetes
Interventions: exenatide once weekly, exenatide once monthly suspension; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Refractory Pancreatic Neuroendocrine Carcinoma
Interventions: Sapanisertib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 405
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 260 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Pancreatic Carcinoma
Interventions: tumoral irradiation, Dendritic cell vaccination; Radiation · Biological
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions: Arginine hydrochloride, Sodium Chloride 0.9%; Drug
Lead sponsor: David K Carroll; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Diseases, Renal Neoplasm, Solid Tumors
Interventions: Entinostat, Pembrolizumab; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 1 Diabetes Mellitus, Hypercalciuria
Interventions: Chlorthalidone; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 12 Years to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Diabetes
Interventions: Diabetes self-management and education; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Type 1 Diabetes Mellitus
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more

Conditions: Healthy, Type 2 Diabetes Mellitus
Interventions: Metformin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Diabetic Macular Edema, Diabetic Retinopathy
Interventions: OCT imaging; Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Wellfleet, Massachusetts • Syracuse, New York + 1 more

Conditions: Macular Degeneration, Diabetic Retinopathy, Hippel-Landau Disease, Mitochondria
Interventions: Feasibility Study - Imaging System; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes, Homeless Persons
Interventions: Diabetes Homeless Medication Support (D-Homes); Behavioral
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage II Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Testicular Seminoma
Interventions: imatinib mesylate, therapeutic conventional surgery, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes
Interventions: PATAS Trifluoroacetate, Placebo; Drug
Lead sponsor: AdipoPharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Chandler, Arizona • Miami, Florida • Port Orange, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 65
States / cities: Mesa, Arizona • Artesia, California • Buena Park, California + 54 more

Conditions: Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, mitomycin C, rubitecan; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: San Ramon, California • Buffalo, New York

Conditions: Obesity, Type 2 Diabetes Mellitus
Interventions: Diabetes Support and Education, gastric bypass surgery, Tissue Control Group; Other · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Improving the Diabetic Health of Black Men: MANUP Feasibility Trial

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Prospective Study FNB, Is It Time To Abandon Cytological Assessment

A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Safety and Efficacy of Chlorthalidone in Type 1 Diabetes

Improving Diabetes Outcomes for Persons With Severe Mental Illness

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits

Metabolic Mapping to Measure Retinal Metabolism

Diabetes Homeless Medication Support Single Arm Treatment Development Trial

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Impact of GBS on CVD in Type 2 Diabetes Mellitus